Tag : ADVANCED HEPATOCELLULAR CARCINOMA

  • CONFERENCE UPDATE
    Systemic therapy for advanced HCC: Selecting the optimal first-line treatment

    The expanding first-line treatment landscape for advanced HCC highlights the need for individualized regimen selection. Beyond efficacy, response durability, toxicity, hepatic reserve, bleeding risk, and tumor characteristics should also guide treatment choice. Optimizing sequential therapy while preserving liver function and future treatment options remains central to improving long-term outcomes.